Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | July 2004 |
| End Date: | November 2009 |
A Phase II Open-labeled, Prospective Study to Determine the Efficacy of Preoperative Chemoradiation With Oxaliplatin/5-FU in Locally Advanced Rectal Cancer Followed by Total Mesorectal Excision and FOLFOX6
RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage
II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated
with improved outcomes. The addition of oxaliplatin (OXA) to neoadjuvant therapy may reduce
distant disease recurrence. Adjuvant treatment with OXA for rectal cancer has been motivated
by benefits demonstrated in stage III colon cancer.
Objective: To determine the feasibility, toxicity, and efficacy of preoperative OXA/5FU and
RT followed by total mesorectal excision (TME) and adjuvant
PURPOSE: This phase II trial is studying the side effects and how well giving neo-adjuvant
combination chemotherapy with radiation works in treating patients undergoing surgery for
rectal cancer.
II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated
with improved outcomes. The addition of oxaliplatin (OXA) to neoadjuvant therapy may reduce
distant disease recurrence. Adjuvant treatment with OXA for rectal cancer has been motivated
by benefits demonstrated in stage III colon cancer.
Objective: To determine the feasibility, toxicity, and efficacy of preoperative OXA/5FU and
RT followed by total mesorectal excision (TME) and adjuvant
PURPOSE: This phase II trial is studying the side effects and how well giving neo-adjuvant
combination chemotherapy with radiation works in treating patients undergoing surgery for
rectal cancer.
OBJECTIVES:
Primary
- To assess the complete pathologic response rate in patients with rectal cancer treated
with radiation, modified neoadjuvant FOLFOX 6 chemotherapy followed by total mesorectal
excision and adjuvant modified FOLFOX 6 chemotherapy.
Secondary
- To observe the overall pathologic response rate in these patients.
- To correlate pathologic staging with preoperative ultrasound and pelvic MRI staging.
- To assess toxic side effects of these regimens in these patients.
- To assess patterns of disease relapse, disease-free survival outcomes, and overall
survival outcomes of these patients.
OUTLINE:
Patients with stage II/III rectal cancer were treated with OXA 60mg/m2 weekly continuous
infusion 5FU of 225 mg/m2/d d1-5 with pelvic RT of 1.8Gy/d for 28 doses. Adjuvant therapy
consisted of 6 cycles of biweekly FOLFOX6.
Surgery: Patients undergo total mesorectal excision by anterior resection or an abdominal
perineal resection within 4 weeks after completion of neoadjuvant therapy.
Adjuvant therapy: Within 4 weeks after surgery, patients receive modified FOLFOX 6
chemotherapy comprising oxaliplatin and leucovorin calcium IV over 2 hours on day 1 and
continuous fluorouracil IV over 46 hours on days 1-2. Treatment repeats every 14 days for 6
courses in the absence of disease progression or unacceptable toxicity.
Patients complete quality of life assessment questionnaires at baseline and at each follow-up
visit.
After completion of study treatment, patients are followed every 3 months for 2 years, every
6 months for 3 years, and annually thereafter.
Primary
- To assess the complete pathologic response rate in patients with rectal cancer treated
with radiation, modified neoadjuvant FOLFOX 6 chemotherapy followed by total mesorectal
excision and adjuvant modified FOLFOX 6 chemotherapy.
Secondary
- To observe the overall pathologic response rate in these patients.
- To correlate pathologic staging with preoperative ultrasound and pelvic MRI staging.
- To assess toxic side effects of these regimens in these patients.
- To assess patterns of disease relapse, disease-free survival outcomes, and overall
survival outcomes of these patients.
OUTLINE:
Patients with stage II/III rectal cancer were treated with OXA 60mg/m2 weekly continuous
infusion 5FU of 225 mg/m2/d d1-5 with pelvic RT of 1.8Gy/d for 28 doses. Adjuvant therapy
consisted of 6 cycles of biweekly FOLFOX6.
Surgery: Patients undergo total mesorectal excision by anterior resection or an abdominal
perineal resection within 4 weeks after completion of neoadjuvant therapy.
Adjuvant therapy: Within 4 weeks after surgery, patients receive modified FOLFOX 6
chemotherapy comprising oxaliplatin and leucovorin calcium IV over 2 hours on day 1 and
continuous fluorouracil IV over 46 hours on days 1-2. Treatment repeats every 14 days for 6
courses in the absence of disease progression or unacceptable toxicity.
Patients complete quality of life assessment questionnaires at baseline and at each follow-up
visit.
After completion of study treatment, patients are followed every 3 months for 2 years, every
6 months for 3 years, and annually thereafter.
Inclusion Criteria
- Histologically proven adenocarcinoma of the rectum with no distant metastases.
- T3-4N0M0, TanyN1-3M0 assessed by clinical exam, TRUS, MRI and CT
- The distal border of the tumor must be at or below the peritoneal reflection, defined
as within 12 centimeters of the anal verge by protoscopic examination.
- No prior chemotherapy or pelvic irradiation.
- ECOG performance status 0-1
- Age 18 to 70 years
- ANC >= 1500/mm3 and platelets >= 100,000/mm3
- Serum creatinine <= 1.5 x ULN; bilirubin <= 1.5 x ULN; ALT<= 2.5 x ULN
Exclusion Criteria
- Pregnant or lactating females; patients not practicing active contraception while
sexually active.
- No other serious medical condition
- A psychiatric disorder that would prohibit the subject from participating fully.
- Peripheral neuropathy > grade 1
- History within the past 5 years of a cancer diagnosis except for non-melanomatous skin
cancers or in situ cervix carcinoma.
- HIV positive patients
We found this trial at
2
sites
New York, New York 10003
Phone: 212-844-8060
Click here to add this to my saved trials
New York, New York 10019
Phone: 212-523-7289
Click here to add this to my saved trials